Site Search

... Assembly was supporting HCR 35 and SCR 29 which, if adopted, would allow for an auditor study to assess health insurance coverage for biomarker testing for Hawaii residents. Currently, insurance coverage for biomarker testing is failing to keep pace with innovation and advancement in treatment. Progress in improving cancer outcomes increasingly involves ...

... February 22, 2024 – A new paper released today in the Journal of Clinical Oncology    finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and ... from them.” ACS CAN is working to improve access to PGx testing through its state advocacy work to expand insurance coverage of comprehensive biomarker testing, which includes PGx testing. Biomarker testing is a critical step toward accessing precision medicine, including targeted therapies; however, not all patients who could benefit ...

... Medicaid, including maintaining coverage for all 7 FDA approved quit methods.     Preserving Cancer Prevention, Treatment and Survivorship  Biomarker testing coverage: ACS CAN will advocate for policies that will expand appropriate coverage of biomarker testing for public and private insurance plans. Insurance coverage for biomarker testing is failing to keep pace with innovations and ...

... Network (ACS CAN) urges legislators to prioritize legislation that will improve access to care for cancer patients by expanding coverage for biomarker testing. “ACS CAN calls on the legislature to increase access to biomarker testing, an essential step in accessing precision medicine treatments by ensuring state regulated health insurance, including Medicaid, ...